Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Accumulated Expenses (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Other Accumulated Expenses for 5 consecutive years, with $5.6 million as the latest value for Q1 2026.

  • For Q1 2026, Other Accumulated Expenses rose 99.5% year-over-year to $5.6 million; the TTM value through Mar 2026 reached $5.6 million, up 99.5%, while the annual FY2025 figure was $7.5 million, 146.39% up from the prior year.
  • Other Accumulated Expenses hit $5.6 million in Q1 2026 for Phathom Pharmaceuticals, down from $7.5 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $7.5 million in Q4 2025 and bottomed at $20000.0 in Q3 2023.
  • Average Other Accumulated Expenses over 5 years is $1.9 million, with a median of $726000.0 recorded in 2024.
  • Year-over-year, Other Accumulated Expenses plummeted 46.15% in 2023 and then soared 8865.0% in 2024.
  • Phathom Pharmaceuticals' Other Accumulated Expenses stood at $151000.0 in 2022, then dropped by 22.52% to $117000.0 in 2023, then soared by 2501.71% to $3.0 million in 2024, then surged by 146.39% to $7.5 million in 2025, then dropped by 25.17% to $5.6 million in 2026.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $5.6 million, $7.5 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.